Literature DB >> 1381873

Development of solid-phase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine protein kinase activity.

K Farley1, H Mett, E McGlynn, B Murray, N B Lydon.   

Abstract

Solid-phase ELISAs for the determination of EGF receptor (EGF-R) and pp60c-src tyrosine protein kinase activity are described. The methods were developed and optimized using purified recombinant EGF-R intracellular domain (ICD) and pp60c-src tyrosine protein kinases. A standardized assay that utilizes poly (GluNa-Tyr)4:1 as substrate and a monoclonal antiphosphotyrosine antibody for detection is described. Assay conditions for both enzymes were optimized with respect to substrate and ELISA plate-coating condition, divalent metal ion preferences, enzyme concentration, apparent kinetic constants for ATP, and reaction linearity. Following standardization, a number of reference tyrosine protein kinase inhibitors were tested in the ELISAs and compared to results obtained using solution-phase radioactive tyrosine protein kinase assays, which are based on the transfer of 32P from [gamma-32P]ATP to synthetic substrate. To enable a comprehensive comparison, IC50 values obtained in the ELISA were compared with values obtained in radioactive assays using both the holo-EGF-R and EGF-R ICD kinases. No substantial qualitative differences between these assays were seen. For many routine tyrosine protein kinase assays, semiquantitative or qualitative measurement of TPK activity is adequate. For such purposes, the ELISAs would be an attractive alternative to radioactive assays.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381873     DOI: 10.1016/0003-2697(92)90056-d

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase.

Authors:  Wei-Ling Chang; Chih-Shiang Chang; Po-Cheng Chiang; Yunn-Fang Ho; Ju-Fang Liu; Kai-Wei Chang; Jih-Hwa Guh
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Attacking cancer at its foundation.

Authors:  Nicholas Lydon
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

3.  An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer.

Authors:  G Rijksen; S S Adriaansen-Slot; G E Staal
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Protocols for Characterization of Cdk5 Kinase Activity.

Authors:  Anita Terse; Niranjana Amin; Bradford Hall; Manju Bhaskar; Binukumar B K; Elias Utreras; Tej K Pareek; Harish Pant; Ashok B Kulkarni
Journal:  Curr Protoc       Date:  2021-10

5.  Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes.

Authors:  Eva Lilienthal; Katharina Kolanowski; Walter Becker
Journal:  BMC Biochem       Date:  2010-05-20       Impact factor: 4.059

6.  An ELISA DYRK1A non-radioactive assay suitable for the characterization of inhibitors.

Authors:  Yong Liu; Tatyana Adayev; Yu-Wen Hwang
Journal:  F1000Res       Date:  2017-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.